Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18884965 | GLP-1R Agonist and Therapeutic Method Thereof | September 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18812060 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | August 2024 | December 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18805490 | COMPOUNDS AS INHIBITORS OF AXL | August 2024 | September 2024 | Allow | 1 | 0 | 0 | No | No |
| 18763302 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | July 2024 | March 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18763210 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18645315 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | April 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18628424 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | April 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18610041 | AZAINDOLE ROCK INHIBITORS | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18593497 | BCL-2 Inhibitor | March 2024 | February 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18436396 | SELECTIVE HYDROGENATION CATALYST OF A,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(2-MERCAPTOPYRIDINE)(PiPr3)2 MOIETIES | February 2024 | May 2024 | Allow | 3 | 0 | 0 | No | No |
| 18424580 | HETEROCYCLIC GLP-1 AGONISTS | January 2024 | December 2024 | Allow | 10 | 2 | 0 | No | No |
| 18544546 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | December 2023 | September 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18539771 | PYRROLO[2,3-C]ISOQUINOLINE-1,2-DIONE COMPOUNDS AS CK2 INHIBITORS | December 2023 | February 2024 | Allow | 2 | 1 | 0 | No | No |
| 18538505 | FGFR3 INHIBITOR COMPOUNDS | December 2023 | September 2024 | Allow | 9 | 1 | 0 | No | No |
| 18524705 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | November 2023 | April 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18506804 | BICYCLIC PYRIDINE DERIVATIVE | November 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18386433 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18386021 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | November 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18500084 | 7-ISOPROPYL 1-ETHYL/METHYL 3-(SUBSTITUTED BENZOYL)-2-SUBSTITUTED INDOLIZINE-1,7-DICARBOXYLATES AS LARVICIDAL AGENTS | November 2023 | March 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18385863 | 9-(2-HYDROXYPYRIDIN-3-YL)-10-(2-PHENYLETHYL)-3,3,6,6-TETRAMETHYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18382829 | SUBSTITUTED 7-AMINO-3-(SUBSTITUTED BENZOYL)INDOLIZINE-1-CARBOXYLATES AS ANTI-TUBERCULAR AGENTS | October 2023 | March 2024 | Allow | 5 | 2 | 0 | No | No |
| 18377348 | 7-ISOPROPYL 1,2-DIMETHYL 3-(SUBSTITUTED BENZOYL)INDOLIZINE-1,2,7 TRICARBOXYLATES AS ADENOSINE RECEPTOR ACTIVE COMPOUNDS | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18472993 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | September 2023 | September 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18462015 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | September 2023 | June 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18240805 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | August 2023 | April 2024 | Allow | 8 | 0 | 0 | No | No |
| 18236237 | 1-SUBSTITUTED BENZOYL-4-BROMOPYRROLO[1,2-a]QUINOLINE-3-CARBOXYLATE DERIVATIVES AS ANTITUBERCULAR AGENTS | August 2023 | December 2023 | Allow | 4 | 2 | 0 | Yes | No |
| 18233259 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | August 2023 | December 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18353422 | INHIBITORS OF NLRP3 INFLAMMASOME | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18347703 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | July 2023 | May 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18215887 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | June 2023 | September 2024 | Allow | 15 | 0 | 0 | No | No |
| 18216280 | COMPOUNDS AND USES THEREOF | June 2023 | January 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18342314 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | June 2023 | January 2024 | Allow | 6 | 0 | 0 | No | No |
| 18339362 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | June 2023 | April 2024 | Allow | 10 | 1 | 0 | No | No |
| 18209405 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | June 2023 | August 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18331492 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | June 2023 | September 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18202622 | BENZAMIDE COMPOUNDS | May 2023 | August 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18322380 | INHIBITORS OF NEK7 KINASE | May 2023 | May 2024 | Allow | 11 | 1 | 0 | No | No |
| 18199019 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | May 2023 | August 2024 | Allow | 15 | 0 | 1 | No | No |
| 18144737 | Azalactam Compounds as HPK1 Inhibitors | May 2023 | October 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18142010 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | May 2023 | October 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 18138917 | PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | April 2023 | February 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18132913 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | April 2023 | January 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18132907 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | April 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18130245 | POLYMORPHS OF THE HYDROCHLORIDE SALT OF LINAPRAZAN GLURATE | April 2023 | August 2023 | Allow | 4 | 1 | 0 | No | No |
| 18191407 | 7-ISOPROPYL 1-ETHYL/METHYL 3-(SUBSTITUTED BENZOYL)-2- SUBSTITUTED INDOLIZINE-1,7-DICARBOXYLATES AS ANTI-TUBERCULAR AGENTS | March 2023 | June 2023 | Allow | 2 | 0 | 0 | No | No |
| 18125262 | PYRROLO[2,3-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | June 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18120876 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | March 2023 | December 2023 | Allow | 9 | 0 | 0 | Yes | No |
| 18179818 | PYRROLO - DIPYRIDINE COMPOUNDS | March 2023 | June 2024 | Allow | 15 | 1 | 0 | No | No |
| 17793350 | CRYSTAL FORM OF AZAINDOLE DERIVATIVE AND USE THEREOF | February 2023 | October 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 18110259 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | February 2023 | May 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18107979 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | February 2023 | March 2024 | Allow | 13 | 2 | 0 | No | No |
| 18164443 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | February 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18160594 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | January 2023 | June 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18154255 | RIP1K INHIBITORS | January 2023 | March 2024 | Allow | 14 | 1 | 0 | No | No |
| 18152049 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | January 2023 | October 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18089498 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | December 2022 | May 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18084245 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18081966 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | December 2022 | September 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18080641 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | December 2022 | May 2023 | Allow | 5 | 1 | 0 | No | No |
| 18078891 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | December 2022 | March 2024 | Allow | 15 | 2 | 0 | No | No |
| 18072497 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | November 2022 | April 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 17984018 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | November 2022 | August 2024 | Allow | 21 | 2 | 0 | No | No |
| 17923160 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | November 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 17978591 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | November 2022 | January 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 17966696 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | October 2022 | July 2024 | Allow | 22 | 1 | 1 | No | No |
| 18045605 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | October 2022 | March 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17960625 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | October 2022 | December 2023 | Allow | 14 | 1 | 0 | No | No |
| 17951651 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | September 2022 | March 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 17950098 | HETEROCYCLIC GLP-1 AGONISTS | September 2022 | October 2023 | Abandon | 13 | 0 | 1 | No | No |
| 17950073 | HETEROCYCLIC GLP-1 AGONISTS | September 2022 | November 2023 | Allow | 13 | 0 | 1 | Yes | No |
| 17933330 | COMPOUNDS AND USES THEREOF | September 2022 | May 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17944757 | COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION | September 2022 | December 2023 | Allow | 15 | 1 | 0 | No | No |
| 17929645 | SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL | September 2022 | October 2023 | Allow | 13 | 0 | 0 | No | No |
| 17876938 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | July 2022 | December 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17867735 | SOLID STATE FORMS OF PEMAFIBRATE | July 2022 | October 2023 | Allow | 15 | 0 | 0 | No | No |
| 17865220 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | July 2022 | April 2024 | Allow | 21 | 1 | 0 | No | No |
| 17863657 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | July 2022 | January 2024 | Allow | 18 | 1 | 0 | No | No |
| 17864326 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | July 2022 | July 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17854089 | 6-AZAINDOLE COMPOUNDS | June 2022 | October 2023 | Allow | 15 | 0 | 0 | No | No |
| 17809984 | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS | June 2022 | April 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17841815 | SUBSTITUTED GUANIDINE COMPOUNDS | June 2022 | July 2023 | Allow | 13 | 0 | 0 | No | No |
| 17837537 | PYRAZOLOPYRIDINONE COMPOUNDS | June 2022 | April 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17805092 | CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF | June 2022 | March 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17751136 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | May 2022 | March 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17751144 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | May 2022 | March 2024 | Allow | 22 | 1 | 1 | No | No |
| 17778701 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | May 2022 | July 2024 | Allow | 26 | 0 | 1 | Yes | No |
| 17663499 | PYRIDINONE-BASED EPIGENETIC MODIFIERS AND USES THEREOF | May 2022 | July 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17777193 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | May 2022 | January 2023 | Allow | 8 | 0 | 0 | Yes | No |
| 17743792 | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | May 2022 | January 2024 | Allow | 20 | 1 | 0 | No | No |
| 17725220 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | April 2022 | September 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17714825 | SOMATOSTATIN MODULATORS AND USES THEREOF | April 2022 | July 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17657841 | ESTROGEN RECEPTOR MODULATORS | April 2022 | January 2024 | Allow | 22 | 1 | 0 | No | No |
| 17656726 | BENZAMIDE COMPOUNDS | March 2022 | July 2023 | Allow | 15 | 0 | 0 | No | No |
| 17705984 | COMPOSITIONS AND METHODS FOR INHIBITING VIRUS PROTEIN 2C ACTIVITY AND FOR PREVENTING AND TREATING NON-POLIO ENTEROVIRUS INFECTION | March 2022 | July 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17704502 | CRYSTALLINE FORM OF A DIHYDROCHLORIDE SALT OF A JAK INHIBITOR COMPOUND | March 2022 | July 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17692923 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | March 2022 | March 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17692695 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | March 2022 | July 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17685753 | FGFR3 INHIBITOR COMPOUNDS | March 2022 | September 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17682763 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES | February 2022 | March 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17679898 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | February 2022 | March 2024 | Abandon | 25 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAHMANI, NILOOFAR.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner RAHMANI, NILOOFAR works in Art Unit 1621 and has examined 270 patent applications in our dataset. With an allowance rate of 88.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 20 months.
Examiner RAHMANI, NILOOFAR's allowance rate of 88.9% places them in the 67% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by RAHMANI, NILOOFAR receive 0.81 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RAHMANI, NILOOFAR is 20 months. This places the examiner in the 87% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +17.8% benefit to allowance rate for applications examined by RAHMANI, NILOOFAR. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 43.2% of applications are subsequently allowed. This success rate is in the 94% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 76.9% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 20.4% are granted (fully or in part). This grant rate is in the 11% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 5.9% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.